Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3807-3815

  Shen, Lijun ^a   Au, Wing Yan ^a   Wong, Kai Yau ^a   Shimizu, Norio ^b   Tsuchiyama, Junjiro ^c   Kwong, Yok Lam ^a   Liang, Raymond H ^a   Srivastava, Gopesh ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MITOCHONDRION; MITOSIS INDEX; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; DNA FRAGMENTATION; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; KILLER CELLS, NATURAL; LYMPHOMA; MITOSIS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PYRAZINES;

EID: 57749106962     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0641     Document Type: Article

References (39)

1. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
2. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94.
3. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216-21.
4. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243-9.
5. Matsuo Y, Drexler HG. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res 2003;27:935-45.
6. Levesque AA, Eastman A. p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007;28:13-20.
7. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005;11:3155-62.
8. Mansilla S, Priebe W, Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 2006;5:53-60.
9. Mansilla S, Bataller M, Portugal J. Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med Chem 2006;6:589-602.
10. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-37.
11. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
12. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
13. Shen L, Liang AC, Lu L, et al. Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma. Blood 2003;102:1553-4.
14. Shen L, Au WY, Guo T, et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007;110:469-70.
15. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and γδ T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001;97:708-13.
16. Tsuchiyama J, Yoshino T, Mori M, et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998;92:1374-83.
17. Vedeckis WV, Bradshaw HD, Jr. DNA fragmentation in S49 lymphoma cells killed with glucocorticoids and other agents. Mol Cell Endocrinol 1983;30:215-27.
18. Griffiths GJ, Dubrez L, Morgan CP, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999;144:903-14.
19. Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997;272:13829-34.
20. 2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005;65:4861-9.
21. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005;65:2795-803.
22. Wolanin K, Magalska A, Mosieniak G, et al. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol Cancer Res 2006;4:457-69.
23. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-81.
24. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005;11:725-30.
25. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 2006;66:9636-45.
26. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-9.
27. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64.
28. Han Z, Hendrickson EA, Bremner TA, Wyche JH. A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. J Biol Chem 1997;272:13432-6.
29. 2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-9.
30. Liang Y, Nylander KD, Yan C, Schor NF. Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2. Mol Pharmacol 2002;61:142-9.
31. Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999;274:21155-61.
32. Del Bello B, Valentini MA, Zunino F, Comporti M, Maellaro E. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 2001;20:4591-5.
33. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9:1145-54.
34. Potapova TA, Daum JR, Pittman BD, et al. The reversibility of mitotic exit in vertebrate cells. Nature 2006;440:954-8.
35. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006;16:1194-200.
36. Josefsberg LB, Kaufman O, Galiani D, Kovo M, Dekel N. Inactivation of M-phase promoting factor at exit from first embryonic mitosis in the rat is independent of cyclin B1 degradation. Biol Reprod 2001;64:871-8.
37. Chesnel F, Bazile F, Pascal A, Kubiak JZ. Cyclin B dissociation from CDK1 precedes its degradation upon MPF inactivation in mitotic extracts of Xenopus laevis embryos. Cell Cycle 2006;5:1687-98.
38. Damia G, Broggini M. Improving the selectivity of cancer treatments by interfering with cell response pathways. Eur J Cancer 2004;40:2550-9.
39. Bassermann F, Peschel C, Duyster J. Mitotic entry: a matter of oscillating destruction. Cell Cycle 2005;4:1515-7.